Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 10/20 | 0.35 |
| ▸ | HTR2C | P28335 | 10/20 | 0.35 |
| ▸ | HTR2B | P41595 | 10/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2572051 | 0.68 | PNMT (0.42) | PNMTHTR2AHTR2CHTR2BMAPT | |
| Hydrochloric Acid SCHEMBL4322406 | 0.67 | PNMT (0.41) | PNMTHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL416988 | 0.67 | PNMT (0.41) | PNMTHTR2AHTR2CHTR2BMAPT | |
| Trifluoroacetic Acid SCHEMBL30321353 | 0.67 | MAPT (0.34) | PNMTHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL28308550 | 0.66 | NSD2 (0.44) | PNMTHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL12706725 | 0.66 | HTR2A (0.49) | PNMTHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4387393 | 0.66 | PNMT (0.36) | PNMTHTR2AHTR2CHTR2B | |
| SCHEMBL4864420 | 0.66 | HTR2A (0.45) | HTR2AHTR2CHTR2B | |
| SCHEMBL10863365 | 0.65 | NOTUM (0.34) | — | |
| Trifluoroacetic Acid SCHEMBL30321293 | 0.65 | HTR2C (0.39) | HTR2AHTR2CHTR2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569282-B2 | Carboxamide compounds and their use | CYTOPATHFINDER, INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2280766-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | CytoPathfinder, Inc. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | JONES SIMON | 2010-11-11 | — | — | US | disclosed |
| WO-2010129843-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | CYTOPATHFINDER, INC. (JP) | 2010-11-11 | — | — | WO | disclosed |
| WO-2009076512-A1 | CARBOXAMIDΞ COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | ALDH1A2, QDPR, PDE6C | PNMT 1118/4885HTR2A 677/4885HTR2C 1386/4885 |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | PNMT 2608/4885HTR2A 455/4885HTR2C 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.